Exploring the Interplay of Chronic Stress and Antiphospholipid Autoantibodies on Trophoblast Function and the Induction of Preeclampsia
The Systemic Autoimmune Diseases Research Group at the Vall d'Hebron Research Institute (VHIR), Barcelona, is seeking an outstanding postdoctoral researcher interested in developing competitive applications for the next Marie Sklodowska-Curie Postdoctoral Fellowships (MSCA-PF).
Marie Skłodowska-Curie Actions – Postdoctoral Fellowships (MSCA-PF)
The Marie Skłodowska-Curie Postdoctoral Fellowships (MSCA-PF) are part of the Horizon Europe programme and support postdoctoral researchers in developing an original research and innovation project through international mobility.
The programme aims to strengthen researchers’ careers through excellent science, international collaboration and interdisciplinary experience, while fostering integration in both academic and non-academic environments. The MSCA-PF call is highly competitive and represents an excellent opportunity to attract international talent and support researchers in consolidating their scientific careers through an ambitious mobility-based fellowship.
The 2026 call closes on 09/09/2026 (17:00 Brussels time). For candidates applying to a European Postdoctoral Fellowship, the fellowship duration is from 12 to 24 months
Full eligibility details: MSCA Postdoctoral Fellowships 2026
Background
Preeclampsia is a severe pregnancy complication characterised by hypertension and multi‑organ dysfunction, representing a major cause of maternal and perinatal morbidity. Increasing evidence indicates that preeclampsia originates from defective embryo implantation and abnormal placentation during early pregnancy. Chronic psychological stress is known to disrupt neuroendocrine and immune homeostasis, while antiphospholipid autoantibodies (aPL) are strongly associated with obstetric complications, including preeclampsia.
Despite these associations, the molecular and cellular mechanisms linking chronic stress, autoimmunity, and placental dysfunction remain poorly understood. Recent advances in human trophoblast organoid models provide a unique opportunity to study early placental development and maternal–fetal interactions in a physiologically relevant system. Understanding how stress hormones and aPL synergistically impair trophoblast function is essential to uncover novel pathogenic pathways involved in preeclampsia.
Objective
The main objective of this project is to determine whether the synergistic action of chronic stress and antiphospholipid autoantibodies disrupts trophoblast function and uterine immune regulation, leading to abnormal implantation, defective placentation, and the development of preeclampsia.
Specifically, the project aims to:
Assess the effects of stress hormones and aPL on trophoblast and uterine NK cell function using human trophoblast organoid models.
Identify molecular, transcriptomic, and proteomic alterations induced by stress and autoimmunity during early placentation.
Validate key pathogenic mechanisms in a preclinical mouse model of stress‑ and autoimmunity‑induced preeclampsia.
Our Group
The project will be hosted by the Systemic Autoimmune Diseases Research Group at VHIR, and will be led by Francesc Miró Mur. The group has extensive expertise in autoimmune diseases, obstetric antiphospholipid syndrome, immune profiling, and translational research. The team has built large clinical cohorts, leads international collaborations, and has a strong publication record in high‑impact journals.
The group collaborates closely with clinicians and international research centres specialising in maternal–fetal medicine, placental biology, and immunology, providing a robust and interdisciplinary training environment for postdoctoral researchers.
Collaborate closely with clinical and basic scientists
Work in experimental design, data analysis, dissemination of results, and preparation of competitive funding applications, including MSCA Postdoctoral Fellowship
The fellow will have access to state-of-the-art facilities, including spectral flow cytometry, spatial transcriptomics, proteomics platforms, and advanced organoid culture systems.
Applicants must hold a PhD degree or have successfully defended their thesis before the call deadline (09/09/2026)
Applicants must comply with the mobility rule, meaning they must not have resided or carried out their main activity (work/studies) in the host country for more than 12 months during the 36 months prior to the call deadline.
Desirable:
Background in placental biology, autoimmunity, or maternal–foetal medicine.
Applicants must have a maximum of 8 years of postdoctoral research experience by the call deadline. This means candidates are generally eligible if they obtained their PhD on or after 10/09/2018 (possible extensions may apply, e.g. parental leave or long-term illness).
Strong experience in cellular and molecular biology techniques.
Demonstrated ability to analyse and interpret complex biological data
Experience with organoid models, flow cytometry, multi‑omics approaches, or animal models.
Scientific writing experience and interest in competitive funding applications
Deadline to apply: 31-07-2026
VHIR embraces Equality and Diversity. As reflected in our values we work toward ensuring inclusion and equal opportunity in recruitment, hiring, training, and management for all staff within the organisation, regardless of gender, civil status, family status, sexual orientation, gender identity and expression, religion, age, functional diversity or ethnicity.
Information on Personal Data Protection:
Data Controller: Fundació Hospital Universitari Vall d’Hebron Institut de Recerca -VHIR-. Purpose: Personnel selection. Legal Basis: Your consent. Data retention period: One year. If you are selected, as long as the employment relationship is in force and legal responsibilities may arise. Data sharing: Does not occur, except for communications necessary to fulfill the purpose and those required by law to public and private bodies. Rights: You can access, rectify, delete, object to, and limit the processing of data, as well as request data portability where applicable, by contacting lopd@vhir.org DPO: dpd@ticsalutsocial.cat More information can be found here
Data Protection Authority: APDCAT
We are a public sector institution that promotes and develops the biomedical research, innovation and teaching at Vall d'Hebron University Hospital, the hospital of Barcelona and the largest of Catalan Institute of Health (ICS). The members of our Board of Trustees are the Catalan Ministry of Health, the Catalan Ministry of Economy and Knowledge (we are a CERCA center), Vall d'Hebron University Hospital, Bank of blood and tissues, the Autonomous University of Barcelona (UAB), of which we are an accredited research institute, and the Vall d'Hebron Institute of Oncology (VHIO), which together with VHIR is part of Accredited Institute of Campus Vall d’Hebron Institute by the Institute of Health Carlos III (ISCIII).
Since its creation in 1994, VHIR works to find solutions to the health problems of society, and contribute to spread them around the world. In more than 20 years we have achieved leadership in biomedical research at hospitals in our country, and we want to be recognised in 2020 as an excellent and competitive European Institute leader in clinical and traslational research linked to a university hospital.
In our institute are working more than 1,300 people, of which over 1,200 doing research and others, around 100, help to do it or transfer it to the society once made, whether in the form of projects, technology transfer and innovation, communication or fundraising, among others.
The best of our institution and its research staff is doing research to solve people’s health problems. Our task is not only basic or translational, we are leaders in clinical research. We have the beds of the hospital separated in less than 50 meters of laboratories and our patients will benefit from our research. In this we believe, and our efforts are focused on it. This is understood by industry leaders who are committed to our hospital, making it a world reference for its first clinical trials.
